In 2014, the PARP inhibitor, Olaparib (AstraZeneca’s Lynparza), was first approved by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) as a cancer treatment targeting advanced ovarian cancers associated with defective BRCA1/2 genes. Here, PARP1 is linked to cancer.